COVID-19 vaccine maker Moderna has announced a deal to supply 25 million doses to Australia, 10 million of which would be delivered this year.
The United States-based biotechnology company announced the deal on Wednesday night, along with revelations it was already in discussions with Australia about potential local manufacturing.
Moderna s vaccine uses the same mRNA technology as the Pfizer jab and has performed broadly similarly in drug trials to date.
A health worker prepares a dose of the AstraZeneca vaccine to be administered at a vaccination center set up in Fiumicino, near Rome s international airport, Thursday, February 11, 2021. AstraZeneca is of the three vaccines authorized by the European Medicines Agency for use in the 27-nation bloc, the other two are Pfizer-BioNtech and Moderna.(AP)
Liberia: SHE-CAN Fellow Deborah Gonkpah Constructs Latrines for Gbartala Residents to Curtail Open Defecation
Liberia: SHE-CAN Fellow Deborah Gonkpah Constructs Latrines for Gbartala Residents to Curtail Open Defecation
Share
Gbartala, Bong County – Deborah Gonkpah, a fellow of SHE-CAN, a United States-based non-profit organization that is building women’s leadership in post-conflict countries, has constructed two pit latrines for residents of Gbartala in Bong County.
Valued at over US$ 600, the latrines will will serve over five hundred residents.
Speaking at the commissioning of the latrines, Gonkpah, a native of Gbartala, said her goal is to contribute to her community and reduce the burden of diarrhoea for people, including men, women, children and vulnerable people.
Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose .
Carsales (ASX:CAR) share price halted to raise funds for major US acquisition
Carsales (ASX:CAR) share price halted to raise funds for major US acquisition
The Carsales.Com Ltd (ASX:CAR) share price is in a trading halt ahead of a major US acquisition. Here’s what you need to know…
James Mickleboro has been a Motley Fool contributor since late 2015. After studying economics at university back home in the United Kingdom, James came to live in Australia and managed to land a job at an Australian fund manager. This was the start of a love affair with Australian equities and he hasn t looked back since. James is part of the CFA Institute s Chartered Financial Analyst program and hopes it teaches him how to become an astute investor which allows him to help others with their own investing. Outside of reading and researching he spends many a late night watching the English Premier League and Seinfeld reruns.